Search Results

Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC << Back Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC CLINICALTRIALS.GOV IDENTIFIER: NCT03647163 Drug/Treatment: VSV-IFNβ-NIS and Pembrolizumab PHASE: I/II STATUS: Recruiting Sponsor: Vyriad, Inc. Collaborator: Mayo Clinic https://www.youtube.com/watch?v=Pw8oSIOt0og Dr. Heloisa Soares Discusses Systemic VSV-IFNβ-NIS and Pembrolizumab DESCRIPTION: Vyriad is sponsoring the safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size details will be a maximum of 40 patients. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jennifer Boughton EMAIL: JBoughton@vyriad.com PHONE: 908-553-3135 Shruthi Naik, PhD EMAIL: snaik@vyriad.com PRINCIPAL INVESTIGATOR: Julian R. Molina, MD, PhD Mayo Clinic

Join NCF for May2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=oSqUgq6QdnM Learn about the latest in high grade neuroendocrine neoplasms and small cell lung cancer with medical oncologist Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program and Co-Director of the Theragnostic Program at the Sylvester Comprehensive Cancer Center, University of Miami. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

<< Go back to the Podcast page EPISODE 9: PRRT (PART II) Download a Transcript of this Episode >> Listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health >> Listen to Episode 10: PRRT (Part Three) with Josh Mailman >> ABOUT THIS EPISODE Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. MEET DR. MARTIN AUERBACH Dr. Auerbach is the Director of Nuclear Medicine at the Westwood and Santa Monica UCLA Hospitals, and Associate Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine at the UCLA Santa Monica and Westwood Hospital, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes, and monitoring of cancer treatment. TOP 10 PRRT QUESTIONS 1. Who is eligible for PRRT? When considering PRRT, is there a minimum or maximum tumor size? What is the effect if a patient receives half the planned dose or a delay in receiving a dose due to low counts? 2. How do you decide on doses of radioactive agents in PRRT? Do they consider the individual’s weight or does everyone get the same dose? 3. What are the side effects of PRRT and how are they managed? 4. Do you continue SSA with PRRT and if so when should one receive it? 5. Can people have carcinoid crisis with PRRT? If so, how is this treated? 6. When or how often are labs done? Which labs and what are you looking for? 7. When do you do imaging? Which imaging to you do? 8. When would you expect to see a response with PRRT and what is the statistics about the shrinkage or response that is expected? 9. For those who have received 4 doses of Luthatera, what happens if/when there is progression, can PRRT be repeated? Can people have more than 4 doses of Lutathera? 10. What is the difference between alpha and beta PRRT? How would you decide between the alpha or beta PRRT? ADDITIONAL RESOURCES Read the LACNETS Blog Post "These Four Letters: PRRT" >> Click here for additional PRRT Resources >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go Back to NCF Events Page "LUNCHEON WITH THE EXPERTS" With Dr. Jonathan Strosberg No registration needed. Date: July 23, 2026 Time: Noon Eastern (9 AM Pacific) Here are the viewing options on Thursday, July 23rd, at Noon Eastern (9 AM Pacific): The Webinar will be live on Facebook Live (under Events) and YouTube Live . Drop your questions for Dr. Strosberg to answer in the comments on Facebook or chat on YouTube. “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available afterward. ABOUT JONATHAN STROSBERG, MD Gastrointestinal Oncology Moffitt Cancer Center, Tampa, Florida Jonathan Strosberg, MD, is a professor in the Department of Gastrointestinal Oncology at the Moffitt Cancer Center in Tampa, FL, specializing in the management of neuroendocrine malignancies. He is also section head of the Neuroendocrine Tumor Division at the Moffitt Cancer Center. He is a graduate of Harvard University and Weill Cornell Medicine. He completed his fellowship in medical oncology and hematology at the Moffitt Cancer Center. Dr. Strosberg has published more than 20 articles and book chapters on the diagnosis and management of neuroendocrine malignancies, including first-author publications in The New England Journal of Medicine , the Journal of Clinical Oncology and The Lancet Oncology . He has also authored 13 articles for UpToDate . He has served as president of the North American Neuroendocrine Tumor Society, and he serves on the National Comprehensive Cancer Network Neuroendocrine Guidelines Committee. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

<< Go back to the Podcast page EPISODE 42: NEUROENDOCRINE CANCER STRAIGHT TALK Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this special episode, medical oncologist and NET expert, Dr. Diane Reidy-Lagunes engages in an open and honest discussion on sensitive topics including sexual health, family planning and end-of-life discussions. She also answers common questions regarding cannabis use with cancer as well as the relationship between sugar and cancer. Dr. Reidy shares information and insights from her decades of experience as well as from the award-winning “Cancer Straight Talk” podcast from Memorial Sloan Kettering Cancer Center (MSKCC) she created and hosted, and she relates these topics to NET patients and their loved ones. MEET DR. DIANE REIDY-LAGUNES Dr. Diane Reidy-Lagunes will join the Department of Medicine (DOM) as chief of the Division of Medical Oncology, effective April 1, 2025. In addition to her role with DOM, Dr. Reidy-Lagunes will also hold an appointment as Associate Vice President for Oncology Services for Duke University Health System. Dr. Reidy-Lagunes comes to Duke from Memorial Sloan Kettering Cancer Center (MSKCC), where she served as the vice chair of Medicine focused on coordination of care in MSKCC Regional Care Network. Her previous roles included president of MSKCC’s Medical Staff, associate deputy physician-in-chief for clinical operations in the Regional Care Network, physician liaison for the Patient and Family Advisory Council on Quality, clinical director for the GI oncology service, and co-director of the Medical Oncology/Hematology Fellowship Program in the Department of Medicine. During the COVID-19 crisis in New York City, she served as chief of clinical care as part of the Hospital Incident Command System at MSKCC. Additionally, she is the creator and host of an award-winning monthly podcast called "Cancer Straight Talk" from MSKCC which connects patients to cancer experts with the goal of having evidenced-based conversations on a variety of topics in cancer care. As a researcher, Dr. Reidy-Lagunes focuses on developing methods to integrate molecular-based therapies into the treatment of neuroendocrine and adrenal tumors. She is a member of the National Cancer Institute Task Force on Neuroendocrine Tumors and the National Cancer Care Network Guidelines, and she is a former board member of the North American Neuroendocrine Tumor Society. She has received numerous awards and honors, including the Paul Sherlock Resident Housestaff Teaching Award and recognition as one of Castle Connolly's Top Doctors. TOP TEN QUESTIONS: What is cancer? Is NET cancer? Should I follow a certain diet? Does sugar feed cancer? Can I exercise if I have metastatic neuroendocrine cancer? What does having neuroendocrine cancer mean for my romantic life? How does it affect dating? What does having neuroendocrine cancer mean for my sexual health? What does having neuroendocrine cancer mean for fertility and family planning? Can I have children? How do I talk to my kids about cancer? How will I know when it’s time for end-of-life discussions? Should I consider cannabis? What advice do you have about improving communication with my doctor? RESOURCES LISTEN MSK’s Cancer Straight Talk Podcast Series with Dr. Diane Reidy Episodes mentioned in this podcast: Episode 2 - Understanding the Basics of the “C-word”: What is Cancer with Dr. Matthew Matasar Episode 6 - Sugar and Cancer: Friend or Foe with Dr. Santosha Vardhana Episode 5 -Making Every Step Count: The Role of Exercise and Cancer Episode 34 - How Exercise Can Help Treat and Prevent Cancer with Dr. Lee Jones Episode 35 - Dating After a Cancer Diagnosis Episode 20 - A Man’s Guide to Sex and Cancer Episode 59 - Preserving Fertility During Cancer Treatment: Options, Costs and Success Rates Episode 56 - How to Talk to Children About Cancer Episode 23 - What’s the Hash on the Little Green Plan (Cannabis) and Cancer? MSK’s Death over Dinner The LACNETS Podcast Episode 37: Supportive Oncology for Neuroendocrine Cancer WATCH https://www.youtube.com/watch?v=ef4GurXr0C8 https://www.youtube.com/watch?v=FiYogD5g_9A DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for Sep2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=_dE7__jhf9I ABOUT The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Download Presentation Slides >>> ABOUT DR. UDHAYVIR SINGH GREWAL Udhayvir Singh Grewal, MD Assistant Professor of Medical Oncology Winship Cancer Institute Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

<< Back Pancreatic NET (PNET) Insulinoma upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs COMPOSE (GEP-NETS) ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients Oral Treatment SWOG S2104: Adjuvant CAPTEM for High Risk pNET Belzutifan/MK-6482 in PNET + PPGL + VHL CDK4/6 Abemaciclib Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers SORENTO™: Subcutaneous Octreotide for GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) SORENTO™: Subcutaneous Octreotide for GEP-NETs STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs << Back Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors CLINICALTRIALS.GOV IDENTIFIER: NCT04750954 DRUG/TREATMENT: lutetium Lu-177 dotatate in combination with M3814 (peposertib) PHASE: 1b STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=2pfbNMs9sZA Dr. Aman Chauhan discusses Lu-177 Dotatate + M3814 DESCRIPTION: This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu-177 dotatate in treating patients with neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu

<< Back Immunotherapy DLL3 DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms CAR T CHM-2101 CAR-T cell for GI Cancers IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Cancer Vaccine Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Immune Checkpoint Inhibitor Combination Studies IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC Oncolytic Virus SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET)

<< Go back to the Podcast page EPISODE 31: CLINICAL TRIALS: EXPECTATIONS VS. REALITIES (PART I & II) Download a Transcript of Part 1 >> Download a Transcript of Part 2 >> ABOUT THIS EPISODE In this 2-part series, we reprise “Navigating Clinical Trials: Expectations vs Realities” with Taymeyah Al-Toubah. This was previously broadcast on August 19th, 2023, as a LACNETS monthly educational webinar. In Part 1, Taymeyah discusses clinical trial terminology, timeline, questions to ask, and misconceptions. In Part 2, Taymeyah answers questions about logistics and practical aspects of clinical trials, such as costs, response time, and follow-up. She also answers frequently asked questions about PRRT trials, including alpha trials. MEET TAYMEYAH AL-TOUBAH, MPH Taymeyah Al-Toubah is a clinical researcher, currently at Moffitt Cancer Center, who has been in the research field for 10 years. She began her career in 2013 while obtaining her bachelors degrees in biomedical sciences and psychology, working in pediatric and neonatal research at Johns Hopkins All Children’s Hospital. In 2016, she shifted her career focus to oncology, beginning with phase I trials and working in all solid tumors. She completed her Master of Public health in epidemiology in 2017 and focused her graduate thesis on neuroendocrine tumors. In 2018, she switched departments to focus exclusively on NETs. From 2018 – 2023, she was the primary NET coordinator in the GI department, managing all clinical trials while leading the GI team, managing the NET clinic coordination amongst the ancillary departments, and working on all retrospective and non-interventional NET research. She has worked on protocol development, database analysis, and manuscript writing, resulting in over 30 published manuscripts and presented her research at several national and international oncology and NET conferences, with oral abstracts at several ENETS and NANETS conferences. In April 2023, she formally transitioned to a new position as a project manager of the NET program where she will continue to mentor new coordinators, while working on protocol development and writing, manuscript writing, non-interventional clinical trials, and retrospective NET research. One of her first major projects will be to curate and develop a master database of all NET patients seen at her institution that will provide the basis for all future NET research to be published at Moffitt. She is currently on the board of one of the first NET patient advocacy groups in Florida (FLaNET Carcinoid Community), which kicked off alongside the Tampa Regional NANETS meeting in November 2022. She is an active member in NANETS on the Continuing Education and Symposium Planning committees. She plans to dedicate the remainder of her career to this disease and community. Her ultimate plan is to attend medical school, specialize in medical oncology, and continue to serve the academic NET community and patient base as a physician and clinical investigator. RESOURCES READ Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event "How to Prepare for Clinical Trials" Info Sheet WATCH https://www.youtube.com/watch?v=CXW71vedhIw DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Lung/Bronchial NETs PRRT/RLT Trials 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE vs Everolimus in Lung NETs Immunotherapies DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms Targeted Therapies Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors << Back CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy CLINICALTRIALS.GOV IDENTIFIER: NCT03375320 DRUG/TREATMENT: Cabozantinib PHASE: 3 STATUS: Closed SPONSOR: National Cancer Institute (NCI) Update - November 9, 2025 https://www.youtube.com/watch?v=balUaCFLceI Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Download the transcript here >>> Update - October 18, 2025 Exelixis Announces Positive Results for CABOMETYX® in Lung and Thymic Neuroendocrine Tumors At ESMO 2025, researchers reported that CABOMETYX® (cabozantinib) significantly delayed tumor growth in people with advanced lung or thymic neuroendocrine tumors—reducing the risk of disease progression or death by 81% compared to placebo. These results come from a subgroup of the phase 3 CABINET trial, which led to FDA and European approvals earlier this year for advanced pancreatic and extra-pancreatic NETs. Why this matters to patients: Lung and thymic NETs are rare and often have few treatment options. CABOMETYX offers a new targeted therapy that may help keep these tumors from growing. Read the full press release here >>> Update - March 26, 2025 A New Treatment Option has been FDA approved for those living with NET. For details, see the press release . UPDATE - September 16, 2024 On Sept 16, 2024, LACNETS interviewed incoming NANETS president, Dr. Jennifer Chan from Dana Farber Cancer Institute following her presentation on the updated, results of the CABINET trial at the medical and scientific meeting, ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. The presentation was titled Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) after Progression on Prior Therapy (CABINET Trial/Alliance A021602): Updated Results Including Progression Free-Survival (PFS) by Blinded Independent Central Review (BICR) and Subgroup Analyses. https://www.youtube.com/watch?v=4iWtw3qmrBs Watch our latest interview on Sept 16, 2024 with Dr. Jennifer Chan at ESMO (the European Society for Medical Oncology) Congress 2024 in Barcelona, Spain. For more information, read our blogpost: Positive Results of the Cabinet Trial Show Cabozantinib As a New Effective Treatment in Advanced Neuroendocrine Tumors . Read more in the latest NEJM article released Sept 16, 2024: Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. UPDATE - October 25, 2023 Dr. Jennifer Chan from Dana Farber Cancer Institute shared the CABINET trial data that showed cabozantinib (CABOMETYX®) helped those with advanced pancreatic NET and extra pancreatic NET (NET outside the pancreas). The results suggest that cabozantinib may be an effective option to treat NET patients, even those who have already tried other therapies. The NET patient community can be hopeful that there will likely be another FDA-approved oral treatment available in the near future. Click here to read the detailed results of the CABINET trial here: Business Wire - "Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 " OncLive - "Cabozantinib Confers PFS Benefit in Previously Treated Advanced Neuroendocrine Tumors" https://www.youtube.com/watch?v=VonfcmeellU Watch this exclusive video interview with Dr. Jennifer Chan at ESMO - European Society for Medical Oncology 2023 in Madrid, Spain. UPDATE - Aug 24, 2023 The Alliance for Clinical Trials in Oncology announced that the CABINET trial (NCT03375320) showed positive findings with cabozantinib having efficacy. The CABINET trial is a phase 3 randomized, double-blinded study evaluating cabozantinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors (PNET) or advanced extra-pancreatic neuroendocrine tumors (carcinoid tumors) who experienced progression after prior systemic therapy. The trial is now being stopped early. It will be unblinded, meaning the patients will find out if they have been receiving placebo and those who have will have the possibility of receiving cabozantinib. The findings will be discussed with the U.S. Food and Drug Administration. Detailed results from the trial will be presented at an upcoming scientific meeting. To read the announcement, go to https://bit.ly/A021602-Interim or https://www.onclive.com/view/cabozantinib-efficacy-prompts-cabinet-trial-unblinding-in-advanced-pancreatic-and-extra-pancreatic-nets. https://www.youtube.com/watch?v=2H_SChk3gxw Dr. Jennifer Chan Discusses CABINET: Cabozantinib DESCRIPTION: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors that, when blocked, may slow tumor growth. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Jennifer A Chan, MD, MPH Alliance for Clinical Trials in Oncology and National Cancer Institute (NCI)